Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2023-08-31 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including adjustments to the number of shares and the list of recipients. This type of filing is a standard regulatory disclosure regarding capital structure and employee compensation instruments, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Remuneration Information' (which is typically for executive compensation disclosures in proxy statements).
2023-08-31 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding capital structure changes and employee compensation via stock options falls under the category of general regulatory filings (RNS) as it does not fit into specific categories like 'Director's Dealing' (which is for insider trades) or 'Share Issue' (which is for new share issuance).
2023-08-28 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a '정정신고' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of shares and the list of recipients. This type of disclosure regarding stock options and capital structure changes falls under the category of regulatory filings related to share-based compensation and capital changes, which is best classified as RNS (Regulatory Filings) as it is a specific corporate disclosure to the financial authorities.
2023-08-22 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details changes in share ownership by major shareholders and special related parties, including reasons such as gifts, market sales, and collateral agreements. This falls under the category of Major Shareholding Notification.
2023-08-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the change in share ownership by an executive (Lee Jae-cheon) of ABL Bio due to gifting shares to a spouse. This falls under the category of Director's Dealing (insider transactions).
2023-08-18 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for ABL Bio, covering the period from January 1, 2023, to June 30, 2023. It contains detailed financial statements, business descriptions, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.